<DOC>
	<DOCNO>NCT01156571</DOCNO>
	<brief_summary>The study design compare efficacy safety profile cangrelor standard care patient require percutaneous coronary intervention ( PCI ) .</brief_summary>
	<brief_title>A Clinical Trial Comparing Cangrelor Clopidogrel Standard Therapy Subjects Who Require Percutaneous Coronary Intervention ( PCI ) ( CHAMPION PHOENIX )</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Cangrelor</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>Patients may include study meet follow criterion : Male nonpregnant female least 18 year age Patients undergo percutaneous coronary intervention ( PCI ) : 1 . Stable angina ( SA ) patient diagnostic coronary angiography within 90 day prior randomization demonstrate atherosclerosis 2 . NonSTSegment Elevation Acute Coronary Syndrome ( NSTEACS ) patient diagnostic coronary angiography within 72 hour prior randomization demonstrate atherosclerosis 3 . STsegment elevation myocardial infarction ( STEMI ) patient ( diagnostic angiography require ) Provide write informed consent Patients exclude study follow exclusion criterion apply prior randomization : Receipt P2Y12 inhibitor time 7 day precede randomization Eptifibatide tirofiban usage within 12 hour precede randomization ( recent dose must administer â‰¥12 hour prior randomization ) Abciximab usage within 7 day precede randomization Receipt fibrinolytic therapy 12 hour precede randomization Increased bleed risk : ischemic stroke within last year previous hemorrhagic stroke ; tumor , cerebral arteriovenous malformation , intracranial aneurysm ; recent ( &lt; 1 month ) trauma major surgery ( include bypass surgery ) ; currently receive warfarin ; active bleeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>